234 related articles for article (PubMed ID: 23613251)
1. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma.
Sun YW; Xuan Q; Shu QA; Wu SS; Chen H; Xiao J; Xiang P; Zhu YP; Wang FL; Zhao ST
Genet Mol Res; 2013 Apr; 12(2):1045-53. PubMed ID: 23613251
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor-C associated with computed tomography used in the diagnosis of lymph node metastasis of bladder carcinoma.
Li Z; Qi F; Miao J; Zu X; He W; Wang L; Qi L
Arch Med Res; 2010 Nov; 41(8):606-10. PubMed ID: 21199729
[TBL] [Abstract][Full Text] [Related]
3. Expression of vascular endothelial growth factor in primary superficial bladder cancer.
Chow NH; Liu HS; Chan SH; Cheng HL; Tzai TS
Anticancer Res; 1999; 19(5C):4593-7. PubMed ID: 10650816
[TBL] [Abstract][Full Text] [Related]
4. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
5. Qualitative and quantitative analysis of angiogenetic factors in transitional cell bladder carcinoma: relationship with clinical course at 10 years follow-up.
Bartoletti R; Cai T; Nesi G; Sardi I; Rizzo M
Oncol Rep; 2005 Jul; 14(1):251-5. PubMed ID: 15944797
[TBL] [Abstract][Full Text] [Related]
6. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
Liu L; Zhu D; Gao R; Guo H
Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Choi YD; Cho NH; Ahn HS; Cho KS; Cho SY; Yang WJ
J Urol; 2007 Mar; 177(3):1174-8. PubMed ID: 17296440
[TBL] [Abstract][Full Text] [Related]
8. [Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in superficial transitional cell bladder carcinoma].
Guo ZH; Mei H; Huang J; Li SY
Ai Zheng; 2003 Mar; 22(3):307-9. PubMed ID: 12654193
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer.
Crew JP; O'Brien T; Bradburn M; Fuggle S; Bicknell R; Cranston D; Harris AL
Cancer Res; 1997 Dec; 57(23):5281-5. PubMed ID: 9393750
[TBL] [Abstract][Full Text] [Related]
10. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
Yang CC; Chu KC; Yeh WM
Urol Oncol; 2004; 22(1):1-6. PubMed ID: 14969795
[TBL] [Abstract][Full Text] [Related]
11. THE SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND SURVIVIN EXPRESSION IN BLADDER CANCER TISSUE AND URINE CYTOLOGY OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER.
Kehinde EO; Al-Maghrebi M; Anim JT; Kapila K; George SS; Al-Juwaiser A; Memon A
East Afr Med J; 2013 Jan; 90(1):19-27. PubMed ID: 26862626
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
Suzuki K; Morita T; Tokue A
Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109
[TBL] [Abstract][Full Text] [Related]
14. [Expressions of survivin and the splice variants survivin-2B and survivin-DeltaEx3 in bladder cancer and their clinical significance].
He XF; Wen DG; Hou JQ; He J; Cen JN
Ai Zheng; 2009 Nov; 28(11):1209-13. PubMed ID: 19895744
[TBL] [Abstract][Full Text] [Related]
15. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
16. Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study.
Makboul R; Refaiy AE; Badary FA; Abdelkawi IF; Merseburger AS; Mohammed RA
Korean J Urol; 2015 Jan; 56(1):31-40. PubMed ID: 25598934
[TBL] [Abstract][Full Text] [Related]
17. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer.
Xi RC; Sheng YR; Chen WH; Sheng L; Gang JJ; Tong Z; Shan Z; Ying GH; Dong LC
J Surg Oncol; 2013 Apr; 107(5):550-4. PubMed ID: 23090902
[TBL] [Abstract][Full Text] [Related]
18. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of survivin in the progression of bladder transitional cell cancer.
Wang Y; Zhu Z; Zeng F; Wang L; Wu Y; Xia W; Xing S
J Huazhong Univ Sci Technolog Med Sci; 2007 Aug; 27(4):444-7. PubMed ID: 17828507
[TBL] [Abstract][Full Text] [Related]
20. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
